Skip to main content

Table 6 Comparing aPLs during hospital admission and after 12 weeks of the first sample in survived positive patients (any positive aPLs test) with thrombotic events (N = 23)

From: Anti-phospholipid antibodies in the setting of thromboembolic events associated with severe COVID-19 pneumonia

aPLs

During admission

(n = 23)

After 12 weeks

(n = 23)

P

LAC

 Positive

 Negative

19(82.6)

4(17.4)

1(4.3)

22(95.7)

< 0.001*4

aβ2GPI IgG

 Positive

8(34.8)

1(4.3)

0.016*4

 Negative

15(65.2)

22(95.7)

 

aβ2GPI IgM

 Positive

 Negative

5(21.7)

18(78.3)

1(4.3)

22(95.7)

0.2194

aCL IgG

 Positive

6(26.1)

1(4.3)

0.1254

 Negative

17(73.9)

22(95.7)

 

aCL IgM

 Positive

 Negative

3(13)

20(87)

0(0)

23(100)

0.2504

  1. aPLs anti-phospholipid antibodies, LAC lupus anti-coagulant, aCL anti-cardiolipin, aβ2GPI anti-β2 glycoprotein, NA not applicable, data are expressed as no. (%)
  2. *P<0.05 (significant value)
  3. 4McNemar test